New materials for better protein treatments
Zwitterionic Dendrimer-modified PEG for Protein Conjugation
This study is exploring a new way to make protein treatments work better for diseases like arthritis, cancer, hepatitis, and gout, so patients can enjoy more effective therapies with fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10482416 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of polymer that can be used to improve the effectiveness of protein-based treatments for various diseases. By combining zwitterionic dendrimers with polyethylene glycol (PEG), the researchers aim to create a novel copolymer that enhances the stability and bioactivity of proteins while reducing potential immune reactions. This approach could lead to better therapeutic options for conditions like arthritis, cancer, hepatitis, and gout. Patients may benefit from treatments that are more effective and have fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from conditions like arthritis, cancer, hepatitis, or gout who may benefit from improved protein therapies.
Not a fit: Patients with conditions not related to protein therapies or those who do not respond to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer protein-based therapies for patients with serious diseases.
How similar studies have performed: Other research has shown promise in using similar polymer modifications to enhance protein therapies, indicating a potential for success in this approach.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Cheng, Chong — State University of New York at Buffalo
- Study coordinator: Cheng, Chong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.